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 Abstract 
  Background and Purpose:  The relationship between apolipoprotein E (ApoE) and onset of vas-
cular dementia remains controversial. The aim of this study was to evaluate the relationship 
between ApoE polymorphism and the onset of subcortical vascular dementia (SVaD) compared 
to Alzheimer’s disease (AD) and normal controls.   Methods:   The study was comprised of 61 pa-
tients with SVaD (42 Binswanger type, 19 lacunar type) and 112 patients with AD (16 early-onset 
AD, 96 late-onset AD) as well as 284 age-, gender- and education-matched normal controls. The 
diagnosis of SVaD was based on modified NINDS-AIREN criteria, and the diagnosis of AD was 
based on NINCDS-ADRDA criteria. ApoE polymorphism was genotyped in all participants.   Re-
sults:  None of the three ApoE alleles was more prevalent in SVaD patients compared to normal 
controls, which was the case when both Binswanger and lacunar types were analyzed sepa-
rately. ApoE     4 did not accelerate the onset of SVaD (OR 1.66, 95% CI: 0.8–3.4), in contrast to a 
significant relation with late-onset AD (OR 3.78, 95% CI: 2.2–6.5).   Conclusion:   Our results sug-
gest that ApoE polymorphism is not associated with the onset of SVaD and that the two sub-
types of SVaD may share similar pathophysiologies.    Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
  Apolipoprotein E (ApoE) transports plasma protein in blood. ApoE     4 has been known 
to be a risk factor of familial  [1]  and sporadic Alzheimer’s disease (AD)  [2, 3] . Along with AD, 
vascular dementia also has been studied to understand the relationship between ApoE    4 
dose and the risk of earlier development of vascular dementia  [4–10] . The results are not con-
firmatory and over half of the reports could not find ApoE     4 as a risk factor for vascular 
dementia   [6, 7, 10]  . Therefore, the relation between ApoE polymorphisms and vascular de-
mentia remains a matter of study. The reason for this may be a lack of homogeneity in the 
diagnosis of vascular dementia due to varying diagnostic criteria and a lack of brain imaging 
in developing countries in which incidence of vascular dementia is higher than in developed 
countries   [11]  . Therefore, studies involving a homogeneous group of patients with vascular 
dementia who underwent brain imaging are needed. Subcortical vascular dementia (SVaD) 
is a subtype of vascular dementia, a relatively homogeneous group characterized by lacunar 
infarctions and white matter hyperintensities (WMHs) as well as focal signs and symptoms 
  [12]  . The pathogenesis has been thought to be based on small vessel pathology of the deep 
brain area   [13]  . It is divided into two subtypes, predominantly ‘white matter cases’, known 
as the Binswanger type, and predominantly ‘lacunar cases’ with multiple lacunae in the deep 
gray matter with white matter lesions   [12]  .
    The objective of this study was to explore the association of ApoE    4 with the age at on-
set of SVaD compared to AD and normal controls. We also tried to determine the differ-
ences between Binswanger and lacunar types in terms of ApoE polymorphism. 
  Subjects  and  Methods 
 Subjects 
  A total of 173 patients (127 females, mean age: 74.28   8   0.52, ages: 52–88) were consecu-
tively recruited from newly diagnosed SVaD and AD patients who had visited the Depart-
ment of Neurology, Daegu Catholic University Medical Center, Daegu, South Korea, be-
tween April 2004 and March 2009. At the time of visit, mean disease duration for patients 
was 2.21   8   2.40 years. Age-, gender-, and education-matched controls (a total of 284 con-
trols, of whom 187 were females, mean age: 73.35   8   5.28, ages: 58–88) were selected from 
community-dwelling, non-demented older individuals after exclusion of cognitive impair-
ment by neuropsychological tests and history of stroke by a neurologist. All participants were 
Korean and gave informed written consent before participating in this study. The Institu-
tional Review Board of the Daegu Catholic University Medical Center approved the study 
protocol in 2007.
  D i a g n o s i s  
  Diagnosis of dementia was made according to DSM-IV criteria   [14]   and that of SVaD 
was based on modified NINDS-AIREN criteria   [12]  . Both Binswanger and lacunar types 
should be absent of cortical and/or cortico-subcortical, non-lacunar territorial infarcts and 
watershed infarcts, hemorrhages, signs of normal pressure hydrocephalus and specific causes 
of white matter lesions as multiple sclerosis, sarcoidosis or brain irradiation. Diagnosis of 
probable AD was made according to NINCDS-ADRDA criteria   [15]  . Exclusion criteria for 
SVaD, AD and normal controls were: (1) history of significant hearing or visual impairment, 
(2) severe psychiatric illnesses, (3) diagnosis of both types of dementia, and (4) AD with mod-
est or severe WMHs or previous stroke evidenced by MRI with cognitive symptoms before 
the onset of the first cerebrovascular event. 3
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    Evaluation of Brain MRI 
  All dementia patients underwent brain MRI. The MRI (MR Excite, GE 1.5 tesla) scans 
included trans-axial T2- and T1-weighted, gradient-echo, fluid-attenuated inversion recov-
ery (FLAIR) and coronal T1-weighted images. Lacunar infarcts were defined as small (  6 3 
mm,   !  15 mm) subcortical infarcts in the chronic stage, located in the basal ganglia, thala-
mus, internal capsule or corona radiata that appeared not to have occlusion of a single pen-
etrating artery   [16]  . They had to show hypointensity on T1 imaging and gliotic rims on T2 
imaging.
    WMH was measured by axial FLAIR images. We rated the degree of WMH in two sep-
arated areas. Lesions in the periventricular area were measured as the longest vertical length 
from the ventricular wall and rated as P1 (  !  5 mm), P2 (  6  5 mm,   !  10 mm) or P3 (  6 10  mm). 
Lesions in the deep white matter were measured as the longest diameter and rated as D1 ( ! 10 
mm), D2 (  6  10 mm,   !  25 mm) and D3 (  6  25 mm). The results were combined to rank the 
severity of WMH. Patients with D3P3 and one to five lacunar infarcts were included as a 
candidate for the diagnosis of Binswanger-type SVaD, and six or more lacunae were needed 
for the diagnosis of lacunar type   [12]  . MRIs with cortical ischemic lesions were excluded 
from the ratings. All MRI scans were rated by a neuroradiologist and a neurologist who did 
not have clinical information on the patients.
  Neuropsychological  Tests 
  The Seoul Neuropsychological Screening Battery (SNSB)   [17]  , a standardized neuropsy-
chological battery, was performed in SVaD and AD subjects. Among these tests, the compo-
nents that could be scored were: digit span (forward and backward), the Korean version of 
the Boston Naming Test, written calculations, the Rey-Osterrieth Complex Figure Test, the 
Seoul Verbal Learning Test, the phonemic and semantic Controlled Oral Word Association 
Test (COWAT) and the Stroop Test. MMSE, Clinical Dementia Rating (CDR) and Geriatric 
depression scales were performed in controls. Clinical assessments include CDR   [18]  , Bar-
thel activities of daily living (B-ADL)   [19]  , Geriatric depression scales   [20]  , and modified 
Hachinski ischemia scales (HIS)   [21]  .
  Age  at  Onset 
  We interviewed the patients and all available informants, reviewed medical records to 
look for previous chronologies of cognitive and behavioral symptoms and asked the patient’s 
caregiver to estimate the duration of symptoms commonly associated with AD   [22]   and 
SVaD. The physician then estimated the age at onset to the nearest half year after resolving 
any discrepant information through further questioning and by relating hypothesized time 
frames to the patient’s life events.
  A p o E   G e n o t y p i n g  
  Genomic DNA was extracted from venous blood. Blood samples from the subjects were 
collected in EDTA-containing tubes, and the ApoE genotype was determined by polymerase 
chain reaction (PCR)   [23]  .
  Statistical  Analysis 
  The comparisons of categorical variables for SVaD and AD with controls were analyzed 
by a     2   test, and continuous variables were analyzed by ANOVA. A Fisher’s exact test was 
computed when the expected frequency of any cell was less than 5. A Student’s t test was used 
to analyze the average for continuous variables for parametric statistics, and the Mann-Whit-
ney U test was performed for nonparametric statistics. The age at onset of each subgroup as-
sociated with each ApoE allele was determined using linear regression analysis. OR and 95% 4
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CI were calculated between subjects with at least one ApoE     4 or at least one ApoE    2  and 
subjects with the ApoE    3/   3 genotype using logistic regression analysis. All statistical anal-
yses were performed using SPSS for Windows version 15.0 (SPSS Inc., Chicago, Ill., USA).
  R e s u l t s  
  General Characteristics  
 As shown in  table 1 , SVaD and AD show significantly lower K-MMSE scores (p  !  0.001), 
CDR (p   !   0.001) and higher Geriatric depression scale scores (p   !   0.001) compared to the 
control subjects. No significant differences were found in scores for K-NPI, B-ADL, S-IADL 
and age at onset between the patients with SVaD or AD, but HIS score was lower in AD pa-
tients (p   !   0.05).
    Frequency Distribution of ApoE Genotypes and Alleles 
  Table 2  shows that the genotype distribution was not significantly different between SVaD 
and controls or between the Binswanger and lacunar types of SVaD. In contrast, the frequen-
cy of ApoE genotype distribution in the AD subjects was statistically different compared to 
controls (p = 0.004). The ApoE     3 allele frequency was lower in the AD group compared to 
controls (p  !  0.001) and the SVaD group (p  !  0.05). The ApoE   4 frequency in the AD patients 
was higher than that of the controls (p  !  0.001) and SVaD patients (p  !  0.05). In contrast, there 
was no significant difference between the SVaD group and the controls (p = 0.314).
    Age at Onset of Each Subgroup of Dementia by ApoE Allele Status 
  In a linear regression analysis with age at onset as the outcome and the four groups and 
the     4 allele as factors, the     4 allele was significantly associated with younger age at onset 
Table 1.   General characteristics of controls and subjects with SVaD and AD
SVaD
(n = 61)
AD
(n = 112)
Controls
(n = 284)
p value
Age 75.0585.46 73.8787.49 73.3585.28 NS
Male/female 17/44 29/83 97/187 NS
Education 3.9284.41 4.7284.76 3.6683.38 NS
Age at onset 72.9086.18 71.6288.02 –N S
K-MMSE 19.3184.37 19.0684.97 24.3783.82d <0.001
CDR 1.0780.33 1.1380.41 0.1580.24d <0.001
CDR/SOB 5.0582.46 5.5983.05 0.1880.39d <0.001
B-ADL 18.5782.53 18.6482.75 –N S
GDS 19.0587.16 17.7586.99 10.3388.05e <0.001
HIS 4.4783.30 3.1582.65 – <0.05
V  alues are means 8 SD. SVaD = Subcortical vascular dementia; AD = Alzheimer’s disease; K-
MMSE = Korean version of the Mini-Mental State Examination; CDR = Clinical Dementia Rating; CDR-
SOB = Clinical Dementia Rating/Sum of Box; B-ADL = Barthel-ADL; GDS = Geriatric depression scale; 
HIS = Hachinski ischemia scales. 
a Result of one-way ANOVA. b Result of 2 test. c Result of Student’s t test. d Significantly different from 
the other two groups (p < 0.001 by post hoc Dunnett’s method). e Significantly different from the other 
two groups (p < 0.001 by Scheffe’s post hoc test).5
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(t = –2.052, p   !   0.05) in only the late-onset AD group. The     3 allele and     2 allele were not 
associated with age at onset in any group (  table 3  ).
    Odds Ratio for Each Dementia Group 
 The cases of three groups were subdivided into two groups: those with at least one ApoE 
    4 and ApoE    3/   3 individuals, and those with at least one ApoE     2 and ApoE    3/  3  indi-
viduals. The OR for the patients carrying ApoE    4/   4 or    3/   4 in AD was 3.46 (95% CI: 
2.0–5.8, p   !   0.001), and in late-onset AD it was 3.78 (95% CI: 2.2–6.5, p   !   0.001) compared 
to those who were carrying ApoE    3/  3.
  Discussion 
  SVaD is a known and common cause of vascular dementia   [12]  , and more research is 
needed to differentiate it with AD and other dementia illnesses. The incidence of all three 
ApoE alleles in SVaD was not different from that of normal controls, in contrast to a signif-
icant difference between AD and normal controls with respect to     4 and     3 allele frequen-
cies. There were also no differences between the Binswanger and lacunar types in allele fre-
quencies and the genotypes of the ApoE polymorphism. On the contrary, the results showed 
an association between the presence of ApoE     4 and younger age at onset of late-onset AD. 
Our results confirmed that there is no association between ApoE polymorphism with age at 
onset of SVaD.
    The presence and gene dose of ApoE     4 was reported to be a risk factor for late-onset 
AD   [1, 2]   in contrast to the controversies between ApoE    4 and vascular dementia. The rela-
tion between ApoE and lipid metabolism   [24, 25]  , which may affect cerebral atherosclerosis, 
indicated that there could be an association between ApoE and vascular dementia. There are 
Table 2.   Distribution of ApoE genotypes and alleles among controls and patients with AD and SVaD
SVaD A D Controls 
(n = 284)
p 
value Binswanger 
type 
(n = 42)
Lacunar 
type 
(n = 19)
total 
(n = 61)
EOAD 
  (n = 16)
LOAD 
(n = 96)
total 
(n = 112)
Genotypes NSa
2/2 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.0) 1 (0.9) 2 (0.7) 0.004b
2/3 2 (4.8) 4 (21.1) 6 (9.8) 1 (6.3) 5 (5.2) 6 (5.4) 31 (10.9) NSc
2/4 0 (0) 0 (0) 0 (0) 0 (0) 3 (3.1) 3 (2.7) 3 (1.1)
3/3 30 (71.4) 12 (63.2) 42 (68.9) 11 (68.8) 51 (53.1) 62 (55.4) 209 (73.6)
3/4 10 (23.8) 2 (10.5) 12 (19.7) 3 (18.8) 31 (32.3) 34 (30.4) 39 (13.7)
4/4 0 (0) 1 (5.3) 1 (1.6) 1 (6.3) 5 (5.2) 6 (5.4) 0 (0)
Alleles
2 2 (2.4) 4 (10.5) 6 (4.9) 1 (3.1) 10 (5.2) 11 (4.9) 38 (6.7)
3 72 (85.7) 30 (78.9) 102 (83.6)e 26 (81.3) 138 (71.9)d 164 (73.2)d 488 (85.9)
4 10 (11.9) 4 (10.5) 14 (11.5)e 5 (15.6) 44 (22.9)d 49 (21.9)d 42 (7.4)
SVa  D = Subcortical vascular dementia; AD = Alzheimer’s disease; EOAD = early-onset Alzheimer’s 
disease; LOAD = late-onset Alzheimer’s disease. 
Results of the 2 test: a p value for SVaD versus controls. b p value for AD versus controls. c p value for 
SVaD versus AD. d p < 0.001 compared to controls. e p < 0.05 compared to AD.6
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several explanations for the relation between ApoE polymorphism and vascular dementia. 
First, there could be interference of mixed-type dementia in detecting vascular dementia. To 
exclude mixed-type dementia, we strictly used temporal relationships between cerebrovas-
cular events and onset of cognitive symptoms as an essential component for the diagnosis of 
SVaD. Additionally, we excluded AD with modest or severe WMHs or previous stroke evi-
dence by the MRI of AD patients. Second, there may be ethnic differences between different 
populations. All patients and controls in this study were Korean and there may be differ-
ences with other ethnicities. As we previously reported, there were ethnic differences for the 
effect of ApoE polymorphism even on patients with AD   [26]  . Therefore, modification of the 
ApoE effect on vascular dementia might occur in some populations. In this study, there were 
no correlations between SVaD and ApoE polymorphism in terms of age at onset. Neither 
ApoE     4 nor ApoE     2 played a role regarding age at onset of SVaD. There were also no dif-
ferences of ApoE allele frequencies between SVaD and the control groups. These results are 
consistent with a previous study   [6, 7, 10]  . Our study again separated SVaD into Binswanger 
and lacunar types to determine possible differences between the two subtypes of SVaD. 
However, both types did not show a significant relationship with ApoE polymorphism. A 
twin study   [10]   and studies of vascular pathophysiology   [27, 28]   strengthened the power of 
our negative findings. Contrary to the results of SVaD, late-onset AD showed a significant 
correlation with onset age and ApoE     4, and overall AD subjects also showed a correlation 
between onset age and ApoE     4. Moreover, AD subjects showed significantly increased    4 
and decreased     3 frequencies compared to those of normal controls which is also in agree-
ment with a previous study   [1–3]  .
    The pathogenesis of SVaD has been thought to be related with small vessel diseases of 
the deep cerebral area   [13]  , and it is divided into two subtypes, the lacunar type   [29, 30]   and 
the Binswanger type   [16, 31]  , by clinical and radiological findings   [12]  . Pathologic findings 
Table 3.   Age at onset of each subgroup of SVaD and AD by APOE allele status
SVaD A D
Binswanger type 
(n = 42)
Lacunar type 
(n = 19)
EOAD 
(n = 16)
LOAD
(n = 96)
AAO n AAO n AAO n AAO n
2 allele status
2 = 2 80.0 (NA) 1
2 = 1 72.5 (10.6) 2 69.5 (5.7) 4 64.0 (NA) 1 73.4 (5.6) 8
2 = 0 74.3 (6.0) 40 70.1 (5.4) 15 56.4 (5.7) 15 74.1 (5.2) 87
3 allele status
3 = 2 73.7 (5.0) 30 71.0 (5.4) 12 55.9 (5.8) 11 74.88 (5.1) 51
3 = 1 75.5 (8.5) 12 67.8 (5.4) 6 60.2 (5.6) 4 73.1 (5.3) 39
3 = 0 70.0 (NA) 1 54.0 (NA) 1 73.5 (5.3) 6
4 allele status*
4 = 2 70.0 (NA) 1 54.0 (NA) 1 72.2 (4.8) 5
4 = 1 76.1 (8.5) 10 64.5 (3.5) 2 59.0 (6.1) 3 72.8 (5.1) 34
4 = 0 73.7 (5.2) 32 70.6 (5.3) 16 56.6 (6.1) 12 75.0 (5.2) 57
Val  ues are means 8 SD. SVAD = Subcortical vascular dementia; AD = Alzheimer’s disease; AAO = 
age at onset. EOAD = early-onset Alzheimer’s disease; LOAD = late-onset Alzheimer’s disease. NA = not 
available. * Significant by linear regression analysis only in the LOAD group (t = –2.052, p < 0.05).7
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of white matter lesions of SVaD include severe gliosis of the white matter and hyalination, 
intimal fibrosis and onion skinning of the long medullary arteries with multiple lacunae  [16, 
32]  . Interference of the frontal subcortical circuit could be the reason for clinical symptoms 
of both types of SVaD. There are several reports presenting the clinical characteristics of 
Binswanger-type SVaD   [29, 30, 33, 34]  . However, to our knowledge, there is no report on the 
clinical and genetic characteristics of lacunar-type SVaD. Relative clinical inhomogeneity of 
the lacunar type and appearance of a new concept of strategic single-infarct dementia such 
as thalamic dementia could be the reason for absence in the study   [35]  . Even though there is 
some inhomogeneity in lacunar-type SVaD, exploring exact clinical and genetic manifesta-
tions of lacunar-type SVaD as well as those of Binswanger-type SVaD has its own signifi-
cance. We thought that the two subtypes of SVaD share genetic and pathophysiological 
mechanisms because of the shared small vessel pathologies. The criteria used in this study 
which obligates at least one lacuna for the diagnosis of Binswanger type could exclude other 
pathophysiologies such as hypoxic encephalopathy or some other lesions mimicking small 
artery disease. In this study, there were no differences between the two types of SVaD in 
terms of ApoE polymorphism, as expected. The lack of a genetic difference between the two 
types in terms of ApoE polymorphism again supports the fact that SVaD has common small 
vessel pathology. The reason why there was no correlation between ApoE polymorphism and 
SVaD could be explained as follows: to begin with, cerebral atherosclerosis and ischemia is a 
multifaceted disorder, and lipoproteins form only one of the many links intervening between 
inception of the lesion and development of the complicated plaque. Other explanations could 
be allelic frequency variation among ethnicities and differences in dietary practices, among 
others. Overall, the results of this study may indicate that small vessel pathology in deep ce-
rebral areas of the brain is not affected by ApoE polymorphism in terms of age at onset and 
ApoE allele frequencies.
    Both types of dementia in our study showed similar neuropsychological test scores in 
terms of K-MMSE, CDR and Geriatric depression scales. It has been thought that SVaD has 
a slow and progressive clinical course, and it is difficult to differentiate SVaD from AD by 
clinical course alone  [12] . Therefore, it may be reasonable that Hachinski ischemia scores are 
only useful to differentiate multi-infarct dementia from AD. However, there was a significant 
difference in the Hachinski ischemia score between AD and SVaD, which could be useful to 
differentiate one from the other. Though the clinical features of SVaD may not show appar-
ent stepwise deterioration, the cognitive deterioration essentially shows a stepwise pattern, 
because of repetitive subcortical ischemic events, which result in minor neurological deficits 
 [36] . A cohort study also showed that patients with MRI-defined SVaD often had more walk-
ing disorders than patients with cortical stroke   [37]  .
  This study has several limitations. First, the relatively small sample sizes for the subtypes 
of SVaD and early-onset AD reduced the power of the study to detect associations between 
ApoE polymorphism and age at onset. In addition, the variable prevalence of some of the 
rare alleles within the subgroups, such as the absence of the     2 homozygotes in the three 
smaller groups or the absence of     4 homozygotes among Binswanger-type SVaD, limits the 
conclusions. On the other hand, these findings may reflect true variation among the sub-
groups not just reflecting random variation. Second, this study uses clinic-based patients and 
our findings may not correlate with that of a population-based study. However, the allelic 
frequencies of the AD patients in our sample are consistent with a previous Korean study  [7] . 
Despite these limitations, this is the first study to investigate the relationship of the two types 
of SVaD with ApoE polymorphism. 
  In summary, this study showed that ApoE polymorphism was not related with the onset 
of SVaD, and it may contribute to the understanding of the pathophysiology of SVaD. 8
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